Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01753479 · ClinicalTrials.gov registry record · NA

Spectroscopy From Duodenum

A NA study of Pancreatic Adenocarcinoma, sponsored by Olympus Corporation.

Completed
Registry status
NA
Development phase
445
Enrollment target
4
Study locations

NCT01753479: Completed NA study of Pancreatic Adenocarcinoma, sponsored by Olympus Corporation.

NCT01753479 is a NA study of Pancreatic Adenocarcinoma that has completed, run by Olympus Corporation. The registered enrollment target is 445 participants, below the 99,458-participant average among 62 other Pancreatic Adenocarcinoma trials with a reported enrollment target (100% lower). The trial reports 4 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01753479, a NA study of Pancreatic Adenocarcinoma, has completed, sponsored by Olympus Corporation.

COMPLETED
Registry status
NA
Development phase
445 participants
Enrollment target
4
Study locations

Study Summary

Purpose of this study is to understand the clinical feasibility of duodenal spectroscopy to adenocarcinoma patients.

Primary Outcome

To clarify that there is the statistically-significant difference between two cohorts.

Conditions Studied

Interventions

  • OTHER Spectroscopy device

Study Locations (4)

Florida

  • Mayo Clinic Florida - Jacksonville

Texas

  • The University of Texas M. D. Anderson Cancer Center - Houston

Brussels Capital

  • Hôpital Erasme - Brussels

Lazio

  • Università Cattolica del Sacro Cuore - Rome

Trial Details

FieldValue
Enrollment Target 445 participants
Start Date 2013-01
Est. Completion 2016-06-30
Phase NA
Olympus Corporation

2 total trials

What the finished NCT01753479 record still lists

NCT01753479 is an interventional study that assigns participants to a tested intervention. The registered 445 participants enrollment target is mid-sized for trials with a published cap, below the 99,458-participant average among 62 other Pancreatic Adenocarcinoma trials with a reported enrollment target (100% lower).

The record links to 1 condition, with Pancreatic Adenocarcinoma appearing as the primary indexed condition, and to 1 intervention - of which Spectroscopy device is the first listed.

NCT01753479 reports a single indexed study location in Florida, Texas, Brussels Capital.

Frequently Asked Questions

What is clinical trial NCT01753479 about?

NCT01753479 is a clinical study titled "Spectroscopy From Duodenum". Purpose of this study is to understand the clinical feasibility of duodenal spectroscopy to adenocarcinoma patients.

What is the current status of trial NCT01753479?

This trial is currently completed. It is a NA study. The enrollment target is 445 participants. The study started on 2013-01. Estimated completion is 2016-06-30.

What conditions does trial NCT01753479 study?

This clinical trial studies the following conditions: Pancreatic Adenocarcinoma.

What interventions are being tested in trial NCT01753479?

The interventions under investigation include: Spectroscopy device (OTHER).

Who is sponsoring clinical trial NCT01753479?

This trial is sponsored by Olympus Corporation, which has 2 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01753479 being conducted?

This trial has 4 study locations across Florida, Texas, Brussels Capital, Lazio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Pancreatic Adenocarcinoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT01753479's enrollment target sits among peer trials

445 10th of 62 higher than 53 of 62 other Pancreatic Adenocarcinoma trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Pancreatic Adenocarcinoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01280994 · 445 participants · Phase 2

    Hyperpolarized 129Xe MRI for Imaging Pulmonary Function

  • NCT03504800 · 445 participants

    OCT in Diagnosis of Irregular Corneas

  • NCT04751435 · 445 participants · NA

    Developing New Educational Materials About Genetic Testing for a Diverse Group of Cancer Patients

  • NCT06348394 · 444 participants · NA

    Intracardiac Versus Transesophageal Echocardiographic Guidance for Left Atrial Appendage Occlusion

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT01753479, the US trial registry maintained by the National Library of Medicine. NCT01753479 (mid enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.